Variants of SARS-CoV-2
Based on Wikipedia: Variants of SARS-CoV-2
In December 2019, the earliest available viral genomes were pulled from the bodies of patients in a city that was just beginning to understand the scale of what was happening to it. At that moment, the virus was a singular, terrifying entity, but it was not static. It was a biological script written in RNA, prone to the typos that come with rapid, chaotic copying. Within months, those typos accumulated. They were not random noise; they were evolutionary edits that changed the virus's ability to bind to human cells, to evade the immune system, and to spread with terrifying efficiency. By the time the World Health Organization stopped using Greek letters for new strains in November 2021, the virus had already fractured into a kaleidoscope of lineages, each with its own distinct genetic signature and its own capacity for harm. The story of SARS-CoV-2 is not merely a chronicle of a pandemic; it is a case study in how a pathogen adapts to the very defenses we build against it, turning the concept of "the virus" into a moving target that requires constant, vigilant redefinition.
To understand why we had to rename the enemy, one must first understand the mechanism of its survival. Viruses generally acquire mutations over time as they replicate. When a new variant appears to be growing in a population, it is labeled an "emerging variant." In the case of SARS-CoV-2, these new lineages often differ from their ancestors by just a few nucleotides—the chemical letters that make up the genetic code. Yet, a single letter change in the wrong place can be catastrophic. The primary battleground is the spike protein, specifically a region known as the receptor-binding domain (RBD). This is the key the virus uses to unlock human cells. When mutations occur here, they can increase the virus's affinity for the ACE2 receptor on our cells, making infection easier. They can also alter the shape of the key just enough that antibodies created by previous infection or vaccination no longer fit, allowing the virus to slip through our immune defenses.
The consequences of these microscopic shifts are macroscopic. An emerging variant can increase transmissibility, meaning it spreads faster. It can increase morbidity and mortality, making the disease more severe. It can evade detection by diagnostic tests or decrease susceptibility to antiviral drugs. Perhaps most insidiously, it can increase the risk of particular conditions like long COVID or multisystem inflammatory syndrome. In the early days of the pandemic, the relatively low number of infections meant fewer opportunities for the virus to mutate. The observation of S-protein mutations was rare. But as the virus infected millions, the sheer volume of replication events provided a massive laboratory for natural selection. The virus evolved. Mutant specimens that were more transmissible or better at evading immunity were naturally selected, outcompeting their ancestors.
The Architecture of Classification
As the virus evolved, the scientific community realized that the old ways of naming were failing. For months, governments and news outlets referred to variants by the country in which they were first identified. The "UK variant," the "South African variant," the "Brazilian variant." This nomenclature was not just clumsy; it was dangerous. It fostered stigma, leading to travel bans and discrimination against nations that had merely done the work of sequencing the virus. The scientific community had a better system, the Pango nomenclature, which assigned lineage names based on evolutionary relationships, but it was too complex for public discourse.
On 31 May 2021, the World Health Organization made a decisive move. They announced Greek-letter names for important strains: Alpha, Beta, Gamma, Delta, and so on. The goal was simple: to provide a way to refer to these dangerous variants that was easy to say, easy to remember, and non-stigmatizing. It was a recognition that language shapes policy and perception. However, this system was reserved for the most dangerous threats. After using all the letters from Alpha to Mu, the WHO paused the Greek naming convention in November 2021, shifting back to scientific nomenclature for newer, less established lineages.
The classification system itself became a critical tool for managing the crisis. Before a variant could be labeled a "Variant of Concern" (VOC), it often passed through stages of scrutiny. It might first be a "Variant of Interest" (VOI) or a "Variant Under Investigation" (VUI). The definitions were fluid, evolving alongside the virus. On 4 October 2023, the WHO published updated definitions that added rigor to these categories. A "Variant Under Monitoring" (VUM) was defined as a variant with a suspected epidemiological growth advantage or community transmission in at least two countries over a 2–4 week period. A "Variant of Interest" required known genetic changes related to greater epidemiological risk and a known growth advantage in at least two WHO regions. A "Variant of Concern" was the highest tier, requiring that the variant satisfy the criteria for a VOI and also demonstrate a risk to global health, such as increased transmission, virulence, or resistance to mitigations like vaccines.
The criteria for these labels were not arbitrary. A VOC, under the October 2023 definition, must show evidence that mutations in the spike protein receptor binding domain substantially increase binding affinity in the RBD-hACE2 complex, supported by genetic data, while also being linked to rapid spread in human populations, supported by epidemiological data. This dual requirement—genetic potential and real-world spread—was the hallmark of a true threat.
The Evolution of the Threat
The history of SARS-CoV-2 variants is a history of escalation. The earliest genomes, collected in December 2019, revealed an ancestral type. Chinese researchers labeled this ancestral type "S" and its dominant derived type "L," reflecting the mutant amino acid changes. Independently, Western researchers carried out similar analyses but labeled the ancestral type "A" and the derived type "B." The B-type mutated into further types, including B.1, which became the ancestor of the major global variants of concern.
The first major wave of concern came with the Alpha variant. It was observed to be significantly more transmissible than previously identified strains. But the virus did not stop there. The Beta variant emerged with mutations that suggested a higher ability to evade immunity. The Gamma variant followed a similar path. Then came Delta. Delta was a game-changer. It was not just more transmissible; it replicated to higher viral loads and caused more severe disease. It swept across the globe, becoming the dominant strain and rendering many previous vaccines less effective against infection, though still effective against severe disease.
The arrival of Omicron in late 2021 marked a new paradigm. Omicron was not just a step up in transmissibility; it was a quantum leap in immune evasion. It carried an unprecedented number of mutations in the spike protein, many of them in the RBD. This allowed it to infect people who had been vaccinated or had previously been infected. It caused a massive surge in cases, overwhelming healthcare systems, even as the severity of individual cases, on average, appeared to decrease compared to Delta. The virus had learned to live with us, not by killing us, but by infecting us so efficiently that our defenses were constantly challenged.
As of 25 June 2025, the landscape had shifted again. The World Health Organization specified JN.1 as a variant of interest, while variants under monitoring included KP.3, KP.3.1.1, JN.1.18, LP.8.1, NB.1.8.1, XEC, and XFG. These names, devoid of Greek letters, reflected the shift to a more scientific, less sensationalist approach. But the biological reality remained the same: these were viruses that had mutated to maintain their replication fitness in the face of rising population immunity. They were the product of a virus that had infected billions, giving it trillions of opportunities to find the perfect combination of mutations to survive.
The Human Cost of Adaptation
While the scientific community debated the nuances of nomenclature and the precise definition of a "Variant of Concern," the human cost of these mutations was being tallied in hospitals, morgues, and empty chairs at dinner tables. The abstract concept of "increased transmissibility" translated into families quarantined together, hospitals running out of beds, and the elderly dying alone. The "ability to evade natural immunity" meant that survivors of the first wave were not safe from the second, or the third. The "increased risk of particular conditions" meant a generation of people grappling with long COVID, a condition that robbed them of their energy, their cognitive function, and their quality of life.
The classification of a variant as a "Variant of High Consequence" was a rare and grim designation. It was reserved for variants where there was clear evidence that the effectiveness of prevention or intervention measures was substantially reduced. This was the nightmare scenario: a virus that made vaccines useless, that rendered monoclonal antibodies obsolete, that turned a manageable illness into a death sentence. While no variant has reached this status to date, the constant threat of it drove the global response.
The definition of these variants was not just a matter of academic curiosity; it dictated the allocation of resources. When a variant was labeled a VOI or a VOC, it triggered field investigations. Submissions from member states were sent to GISAID, the global database of viral sequences, where scientists from around the world could analyze the data. These investigations were the frontline of the pandemic response. They determined whether travel restrictions needed to be tightened, whether vaccine formulations needed to be updated, and whether public health messaging needed to change.
The CDC in the United States often defined its variants of concern slightly differently than the WHO. For example, the CDC de-escalated the Delta variant on 14 April 2022, while the WHO did so on 7 June 2022. These discrepancies highlighted the complexity of managing a global pandemic with local realities. What was a threat in one region might have been controlled in another. What was a priority for one health authority might have been a lower priority for another. Yet, the underlying biology was universal. The virus did not respect borders.
The Origin and the Future
Despite the vast amount of data collected on SARS-CoV-2, the origin of the virus has not been definitively identified. However, the emergence of SARS-CoV-2 is widely believed to have resulted from recombination events between a bat SARS-like coronavirus and a pangolin coronavirus through cross-species transmission. This zoonotic spillover was the spark that ignited the pandemic. The earliest available viral genomes, collected from patients in December 2019, allowed researchers to compare these early strains with bat and pangolin coronavirus strains to estimate the ancestral human coronavirus type. This ancestral genome was the starting point from which all subsequent variants would evolve.
The journey from that ancestral strain to the variants of 2025 is a testament to the power of evolution. The virus has shown a remarkable ability to adapt. It has learned to bind more tightly to human cells. It has learned to hide from antibodies. It has learned to spread in the face of lockdowns, masks, and vaccines. Each variant has been a response to the pressure exerted by human society. The more we tried to stop it, the more it changed.
As of 2026, the virus continues to circulate. The variants of concern may have faded into history, replaced by new lineages with new mutations. The Greek letters are no longer used for the newest threats. Instead, we rely on the Pango nomenclature and the Nextstrain and GISAID systems to track the virus's evolution. The definitions of VOI and VUM have been refined to capture the nuances of risk in a world where the virus is endemic. But the fundamental challenge remains. As long as the virus continues to replicate, it will continue to mutate. As long as it mutates, there will be new variants.
The story of SARS-CoV-2 variants is a reminder of our vulnerability. We are not the masters of this biological landscape; we are participants in it. The virus is a force of nature, driven by the simple imperative to survive and reproduce. Our defenses—vaccines, drugs, public health measures—are our attempts to impose order on that chaos. But the virus is always one step ahead, always ready to find a new way in. The variants of 2025, with their specific mutations and their specific risks, are just the latest chapter in a story that began in the winter of 2019 and will likely continue for years to come.
The science of variant classification is a tool for survival. It allows us to anticipate the next wave, to prepare our healthcare systems, to update our vaccines, and to protect the most vulnerable. It is a race against time, a race against evolution, and a race against the unknown. But it is a race we must run. Because the cost of losing is measured in lives, in suffering, and in the fragility of our global society. The variants are not just lines of code in a genome; they are the agents of change that have reshaped the world. And as we look to the future, we must remain vigilant, ready to identify the next threat, to name it, to study it, and to defeat it.
"The variant submissions from member states are then submitted to GISAID, followed by field investigations of the variant."
This simple sentence encapsulates the global effort required to track the virus. It is a collaborative, data-driven, and relentless pursuit of knowledge. It is the work of thousands of scientists, public health officials, and policymakers who are dedicated to understanding the enemy. And it is the work that will continue, as long as the virus continues to evolve.
The end of the Paxlovid era may have been debated, but the era of the variant is not over. It is a permanent feature of our reality. We must learn to live with it, to adapt to it, and to fight it with the same determination and ingenuity that we have shown in the past. The variants of SARS-CoV-2 are a testament to the resilience of life, but also to the resilience of the human spirit. We have faced this virus before, and we will face it again. But we will not be the same. We will be smarter, faster, and better prepared. And that is the only victory that matters.